Singapore, June 30 -- Neurizon Therapeutics, a clinical-stage biotech company based in Australia, has announced the development of a new oral liquid formulation of NUZ-001, its lead investigational therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS).

For many patients, especially those experiencing bulbar onset or progressive difficulty swallowing, tablet-based medication can become increasingly hard to manage as the disease advances. The oral liquid formulation provides an important alternative, ensuring more patients can continue to benefit from NUZ-001 throughout their journey.

Developed in direct response to feedback from patients and carers, this formulation reflects Neurizon's belief that the patient voice should guid...